» Articles » PMID: 36611166

A Comprehensive Review of COVID-19 Symptoms and Treatments in the Setting of Autoimmune Diseases

Overview
Journal Virol J
Publisher Biomed Central
Specialty Microbiology
Date 2023 Jan 7
PMID 36611166
Authors
Affiliations
Soon will be listed here.
Abstract

After the first reporting of the index case of Severe Acute Respiratory Syndrome (SARS)-CoV-2-associated disease at the end of December 2019, the virus spread quickly throughout the world, prompting the WHO on 11 March 2020 to declare the disease a global pandemic. The coronavirus disease 2019 (COVID-19) pandemic, raises concerns for all people, mainly for susceptible population. People with pre-existing diseases, especially individuals with autoimmune disorders, are more at the risk of SARS-CoV-2 infection because of compromised immune system due to frequent use of immunosuppressive drugs and steroids. Patients with autoimmune diseases and their physicians have concerns about these patients' healthcare, since they are at a higher risk for COVID-19 infection, may show severe complications of COVID-19, and may experience probable flares of their pre-existing disease. Even though there have been several studies discussing the relation between COVID-19 and various types of autoimmune diseases, it cannot be ascertained that all patients with autoimmune diseases experience more severe complications of COVID-19 and have more hospitalization or mortality rate. The situation depends on each patient's condition, such as the type and the severity of the underlying autoimmune disease and the kind of treatment they receive. In the present review, we have discussed the effects of COVID-19 pandemic on patients with different autoimmune diseases and their relative concerns about their treatments. As a result, we have reviewed further considerations that should be taken into account for these patients during the pandemic or when they are infected with COVID-19.

Citing Articles

Randomised, Placebo-Controlled, Double-Blind Trial to Assess Efficacy and Safety of ELOM-080 in Outpatients with COVID-19.

Dreher M, Heier H, Kienle-Gogolok A, Roschmann-Doose K, Simon J, Singhal R Adv Ther. 2025; 42(2):1237-1250.

PMID: 39812754 PMC: 11787264. DOI: 10.1007/s12325-024-03093-4.


Dysregulated autoantibodies targeting AGTR1 are associated with the accumulation of COVID-19 symptoms.

Fonseca D, Japel M, Gyamfi M, Filgueiras I, Baiochi G, Ostrinski Y NPJ Syst Biol Appl. 2025; 11(1):7.

PMID: 39805853 PMC: 11730328. DOI: 10.1038/s41540-025-00488-z.


Pharmacophore modeling and QSAR analysis of anti-HBV flavonols.

Baei B, Askari P, Askari F, Kiani S, Mohebbi A PLoS One. 2025; 20(1):e0316765.

PMID: 39804828 PMC: 11730388. DOI: 10.1371/journal.pone.0316765.


Rapid detection of cardamom mosaic virus in crude plant extracts using reverse transcription-recombinase polymerase amplification-lateral flow assay (RT-RPA-LFA).

Greeshma M, Bhat A 3 Biotech. 2025; 15(1):28.

PMID: 39744016 PMC: 11685339. DOI: 10.1007/s13205-024-04191-4.


Unmasking the impact of COVID-19 on the mental health of college students: a cross-sectional study.

Gandhi S, Jordan A, Glaman R, Morrow B Front Psychiatry. 2024; 15:1453323.

PMID: 39624514 PMC: 11608972. DOI: 10.3389/fpsyt.2024.1453323.


References
1.
Shaikh M, Jordan N, DCruz D . Systemic lupus erythematosus. Clin Med (Lond). 2017; 17(1):78-83. PMC: 6297589. DOI: 10.7861/clinmedicine.17-1-78. View

2.
Pahalyants V, Murphy W, Klebanov N, Lu C, Theodosakis N, Klevens R . Immunosuppressive biologics did not increase the risk of COVID-19 or subsequent mortality: A retrospective matched cohort study from Massachusetts. J Am Acad Dermatol. 2021; 86(1):252-255. PMC: 8428982. DOI: 10.1016/j.jaad.2021.08.065. View

3.
Matucci-Cerinic M, Bruni C, Allanore Y, Clementi M, Dagna L, Damjanov N . Systemic sclerosis and the COVID-19 pandemic: World Scleroderma Foundation preliminary advice for patient management. Ann Rheum Dis. 2020; 79(6):724-726. DOI: 10.1136/annrheumdis-2020-217407. View

4.
Aghbash P, Eslami N, Shamekh A, Entezari-Maleki T, Baghi H . SARS-CoV-2 infection: The role of PD-1/PD-L1 and CTLA-4 axis. Life Sci. 2021; 270:119124. PMC: 7838580. DOI: 10.1016/j.lfs.2021.119124. View

5.
Akiyama S, Hamdeh S, Micic D, Sakuraba A . Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis. Ann Rheum Dis. 2020; 80(3):384-391. DOI: 10.1136/annrheumdis-2020-218946. View